Dr Reddy's Laboratories today said it has received 13 observations from the US health regulator for its formulation manufacturing facility at Duwada, Visakhapatnam.
"The audit of company's formulation manufacturing facility at Duwada, Visakhapatnam, by the US FDA, has been completed on March 8, 2017. The company have been issued a Form 483 with 13 observations, which the company is addressing," Dr Reddy's Laboratories said in a BSE filing.
The company, however, did not specify the observations.
Shares of Dr Reddy's Laboratories were trading 4.21 per cent lower at Rs 2,731.35 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
